絞り込み

16533

広告

映画「007」の次回作監督は日系アメリカ人 (NHK)

世界的に人気のスパイ映画「007」シリーズの次回作の監督に、日系アメリカ人のキャリー・フクナガさんが選ばれました。 「007」シリーズの25作目の監督に選ばれた...

  1. [企業] 武田 Molecular Te...
  2. 匿名化サービス悪用、追跡困難か Zaif...
  3. [企業] 全身投与で病変のみに作用する治...
  4. G7、海のプラごみ対策議論 (デイリース...

ニュース一覧

Direct Oral Anticoagulants in End-Stage Renal Disease.

著者 Klil-Drori AJ , Tagalakis V
Semin Thromb Hemost.2018 Jan 10 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (60view , 0users)

Full Text Sources

Patients with end-stage renal disease (ESRD) were excluded from pivotal clinical trials with oral anticoagulants. While such patients are at an increased risk of venous and arterial thromboembolism, their risk of bleeding is also elevated. It is thus of little surprise that stroke prevention with vitamin K antagonists (VKAs) in ESRD patients with atrial fibrillation is controversial, with observational evidence ranging from beneficial to harmful. This uncertainty extends to the less studied use of VKAs for venous thromboembolism in ESRD. The direct oral anticoagulants (DOACs) apixaban and rivaroxaban have now permissive labeling in the United States for atrial fibrillation in patients with ESRD; this expanded labeling has not yet occurred either in Europe or for venous thromboembolism. This review summarizes the current evidence for the pharmacology of DOACs in ESRD as well as their utilization and safety in patients with ESRD and atrial fibrillation.
PMID: 29320795 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード